Since, Erlotinib is frequently used in clinic for treatment of the NSCLC tumors with activating mutation in the kinase domain of EGFR [4], we chose the HCC 827 NSCLC cells with EGFR exon 19 (Δ19) mutation for generation of the Erlotinib-resistant cells. This evidence concerns the gene EGFR and hepatocellular carcinoma.